

# *C9orf72* and the Care of the Patient With ALS or FTD

## Progress and Recommendations After 10 Years

Jennifer Roggenbuck, MS, CGC

*Neurol Genet* 2021;7:e542. doi:10.1212/NXG.0000000000000542

### Correspondence

J. Roggenbuck  
jennifer.roggenbuck@osumc.edu

### Abstract

The 2011 discovery of the pathogenic hexanucleotide repeat expansion (HRE) in *C9orf72*, the leading genetic cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), marked a breakthrough in the effort to unravel the etiology of these conditions. Ten years later, clinicians are still working to integrate the implications of this discovery into the care of individuals with ALS and/or FTD. Consensus management guidelines for ALS do not comprehensively address the issue of genetic testing, and questions remain about whom to test, what counseling should be provided before and after testing, laboratory methods, and test interpretation. These challenges have contributed to inconsistent clinical practices and present barriers to patients wishing to access testing. This review summarizes the clinical impact of the discovery of the *C9orf72* HRE, outlines ongoing challenges, and provides recommendations for *C9orf72* testing, counseling, and research.

---

From the Departments of Neurology and Internal Medicine, The Ohio State University Wexner Medical Center, Columbus.

Go to [Neurology.org/NG](https://Neurology.org/NG) for full disclosures. Funding information is provided at the end of the article.

The Article Processing charge was funded by the Ohio State University Wexner Medical Center.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

## Glossary

ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia; HRE = hexanucleotide repeat expansion; RP-PCR = repeat-primed PCR.

Genetic studies as early as 2006 established that amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), 2 seemingly distinct neurodegenerative disorders, were linked to chromosome 9p21.<sup>1</sup> In 2011, 2 groups independently identified a G<sub>4</sub>C<sub>2</sub> hexanucleotide repeat expansion (HRE) in the first intron (or promoter region, depending on transcript) of *C9orf72* and demonstrated that this expansion underlies a significant proportion of familial and sporadic ALS, FTD, and combined ALS-FTD. Normal alleles were reported to contain no more than 23 repeats, with pathogenic expansions having greater than 30 repeats. Intermediate alleles of 23–30 repeats were reported to have uncertain pathogenicity.<sup>2,3</sup> The mechanism of disease is the focus of active investigation and may include loss of function of the *C9orf72* protein and the formation of RNA foci and dipeptide repeat proteins. The mechanisms may act in concert and/or differ depending on repeat size.<sup>4</sup> Antisense oligonucleotide, small molecule, and other therapies hold promise for slowing disease progression in patients with the *C9orf72* HRE.

Most patients with the *C9orf72* HRE present clinically with ALS or behavioral variant FTD, or a combination of both. The spectrum of phenotypes includes rapidly and slowly progressive disease, and clinical presentations may differ from classic ALS or FTD.<sup>5,6</sup> In families, the *C9orf72* HRE is transmitted in an autosomal dominant manner, with age-dependent and incomplete penetrance. Age at onset and presenting symptomatology is variable, even among members of the same family.<sup>7</sup> Notably, some individuals with a HRE in the clearly pathogenic range remain symptom free, even in old age.<sup>8</sup> The *C9orf72* HRE is by far the most common known genetic cause of ALS and FTD, far exceeding the prevalence of pathogenic variants in any other gene, although frequencies vary greatly by geoancestry. The highest HRE frequencies are observed in Europe, reported in 40% of familial and 6% of sporadic cases of ALS and in 18% of familial and 6% of sporadic cases of FTD in European patient cohorts. The HRE is rarely found in Asia.<sup>9–13</sup>

## *C9orf72* in the Clinic: Progress and Challenges

### Current Status of Testing and Counseling

Clinical testing for the *C9orf72* HRE has been available since 2012.<sup>14</sup> Currently available commercial assays include repeat-primed PCR (RP-PCR), fluorescent amplicon length analysis, and Southern blot. United States ALS management guidelines do not address the offer of genetic testing, whereas European guidelines specify that testing be offered to patients with familial disease.<sup>15,16</sup> Several published clinician surveys suggest

a growing consensus to offer genetic testing to patients with familial ALS, but the offer of testing to the typical ALS patient with sporadic disease remains inconsistent.<sup>17</sup> Table 1 summarizes published clinician practice surveys.

Patient experience and attitudes toward genetic testing in ALS have been investigated in several studies. In a 2015 survey of US ALS patients, 33.4% of respondents (n = 449) reported being offered genetic testing, including 68.9% of those with familial and 27.5% of those with sporadic ALS. Respondents expressed positive attitudes toward genetic testing and perceived benefits to ALS patients, families, the medical community, and society; this was most pronounced in those who reported a positive family history of ALS. Among those who had testing, those who received positive and negative results reported equally favorable experiences, suggesting that those who get “bad news” maintained a favorable outlook about the benefits of testing.<sup>18,19</sup> Attitudes toward presymptomatic ALS testing have also been studied; in a study of family members of persons with ALS, 60% indicated they would have presymptomatic testing if offered.<sup>20</sup>

### Challenges in Laboratory Detection and Interpretation of the HRE

PCR-based assays for detection of the HRE are widely used in commercial laboratories, but their accuracy has been questioned. In a 2014 blinded study, only 5/14 laboratories reported PCR-based *C9orf72* results in complete concordance with the reference Southern blot result, and both false negative and false positive results were identified.<sup>21</sup> Insertions and deletions adjacent to the repeat have been shown to interfere with detection of the expansion using PCR-based assays.<sup>22</sup> Southern blot has been advocated as the gold standard for clinical testing.<sup>6</sup> Currently, it is the only commercial test capable of sizing large repeats, but few laboratories offer it, and it may not detect intermediate repeats or small expansions.<sup>23</sup> In the future, alternative methods for detecting and sizing the HRE may be commercially available, such as short- and long-read sequencing techniques that are currently used in the research setting.

In addition, laboratory interpretation and reporting of the HRE is inconsistent. Published surveys of commercial laboratory tests reveal that cutoffs for normal, intermediate, and expanded alleles varied widely. Cutoffs for intermediate alleles ranged from 20 to several hundred; cutoffs for pathogenic alleles ranged from >23 to >700 (figure). Intermediate or small expansions could therefore be interpreted differently by different laboratories, and such cases have been reported.<sup>23,24</sup> There is currently no validated cutoff that differentiates between pathogenic and nonpathogenic alleles.

**Table 1** Percentage of Clinicians Offering ALS Genetic Testing, by Family History Indication, in Practice Surveys (Adapted from Klepek et al., 2019)

Study	n	fALS	sALS
Byrne et al., 2012	95	67.0%	10.3%
Arthur et al., 2016	43	93.0%	30.2%
Vajda et al., 2017	167	90.2%	49.4%
Klepek et al., 2018	65	92.9%	36.9% (sALS); 57.0% (dALS)

Abbreviations: ALS = amyotrophic lateral sclerosis; dALS = ALS with family history of any dementia; fALS = familial ALS; sALS = sporadic ALS.

Finally, the *C9orf72* HRE shows somatic and germline instability further complicating result interpretation. For example, expansion sizes as measured in blood may differ from those in relevant neural tissues.<sup>25</sup> Intermediate alleles identified in patients with ALS may be incidental or could be associated with larger, pathogenic expansions in the brain.<sup>6</sup> The size of the HRE as measured in blood may change over time in the same individual,<sup>26</sup> although this has not been observed to increase from the normal to pathogenic range. Repeat instability also occurs in the germline, but evidence does not support the common occurrence of genetic and clinical anticipation as seen in other repeat expansion disorders such as myotonic dystrophy type 1 and Fragile X syndrome.<sup>26</sup> Contraction of the HRE in successive generations has recently been demonstrated, particularly with paternal transmission.<sup>26,27</sup>

### Unanswered Questions Regarding Disease Expression

When patients with *C9orf72* HRE present with symptoms of motor neuron disease, the phenotype is often indistinguishable from classic ALS. Although the most common cognitive phenotype is behavioral variant FTD, a range of cognitive-behavioral presentations are observed, including psychotic features such as delusions and hallucinations. Patients presenting with neuropsychiatric changes may not be recognized and diagnosed with *C9orf72*-related disease.<sup>6</sup> Repeat number has not been robustly shown to correlate with age at onset, disease duration, or clinical

presentation (ALS and/or FTD),<sup>25,28</sup> although this remains an active area of investigation.

Early family studies suggested that nearly all HRE carriers develop disease by the age of 80 years.<sup>9,29</sup> However, the identification of the HRE in 0.2%–0.6% of unaffected controls and the presence of elderly, neurologically healthy obligate HRE carriers in affected families support incomplete penetrance.<sup>5,25,29</sup> Penetrance has not been established to correlate with repeat size.<sup>26</sup> A recent study modeled HRE penetrance in a large cohort drawn from published literature, concluding that lifetime penetrance is incomplete (estimated at ~90% by the age of 80 years).<sup>29</sup> Oligogenic inheritance has been proposed to contribute to the variable penetrance of the HRE and other pathogenic ALS variants; however, evidence in support of this model is lacking.<sup>30</sup>

### Incomplete Knowledge of *C9orf72* HRE Prevalence


HRE frequencies are highest in Scandinavian countries<sup>9,31</sup> and lowest in Asian populations.<sup>9,10,12,13,31</sup> HRE frequencies in other populations, however, including non-White or admixed populations in the United States and Europe have not been studied extensively. Tables e-1 and e-2 (links.lww.com/NXG/A345) summarize published frequencies by geoancestry.

## Practice Recommendations

### All Persons With ALS and/or FTD of European Geoancestry Are Candidates for HRE Testing

Many persons with ALS and/or FTD wish to know as much as possible about why they developed the condition and the risk that family members could also be affected. A genetic diagnosis enables clinicians to provide personalized, specific answers to these questions, and affected persons and their relatives may feel empowered by the knowledge and the opportunity to act, whether for reproductive planning, pre-symptomatic testing, or research participation. Testing of persons with ALS and/or FTD, but without a known family history of either condition, identifies the HRE in up to 10%.<sup>32</sup> HRE testing should be offered to any patient who meets

**Figure** Variable Interpretations of the *C9orf72* Hexanucleotide Repeat Number Among Commercial Laboratories



**Table 2** Incidence of *C9orf72* HRE in Patients With ALS, FTD, and ALS/FTD of European Geoancestry

Family history	Proband with ALS	Proband with FTD	Proband with ALS/FTD
ALS and/or FTD	40%–50% <sup>a,9,39</sup>	18% <sup>9</sup>	56% <sup>31</sup>
No ALS/FTD	6%–10% <sup>9,32,39</sup>	6% <sup>9</sup>	14% <sup>31</sup>

Abbreviations: ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia; HRE = hexanucleotide repeat expansion.

<sup>a</sup> In patients with ALS and a family history of any dementia, 12%.

clinical diagnostic criteria for either condition.<sup>33</sup> The current availability of clinical trials targeting HRE pathology in ALS underscores the importance of HRE testing in ALS management. Although pathogenic variation in more than 30 other genes has been established to cause ALS and/or FTD, these account for a smaller proportion of cases in populations of European descent.<sup>34</sup> In addition, uncertain or indeterminate results are rare with *C9orf72* HRE testing, occurring in less than 1% cases; most patients get a clear positive or negative result.

### Amplicon Length Analysis With Bidirectional RP-PCR Is Suitable for Large Scale HRE Testing

The RP-PCR assays widely used in commercial testing for the HRE are cost-effective, rapid, and identify patients with an expanded allele by revealing a “saw-tooth pattern” when a significant repeat expansion is present. However, as noted previously, interpretation of *C9orf72* RP-PCR results is not always straightforward. Amplicon length analysis, however, is a reliable method for sizing intermediate and smaller HREs and may be helpful in resolving cases in which sequence variants interfere with RP-PCR results. A combination of amplicon-length analysis and bidirectional 5′ and 3′ RP-PCR is recommended to obtain the highest level of sensitivity and specificity.<sup>21,22</sup> The use of 2 RP-PCR assays from both the 3′ and 5′ end of the repeat region and 2 nonoverlapping primer sets for amplicon length analysis buffers against potential allele drop out due to neighboring sequence variants and aids in determining zygosity in patients with HRE (Luke Drury, PhD, written communication, August 20, 2020). Although this approach cannot size large expansions, there are currently no established correlations between expansion size and disease expression. This combined technique currently represents the best approach to the clinical detection of the *C9orf72* HRE on a large scale.

Southern blot or advanced sequencing techniques may be necessary in rare cases, such as those in which RP-PCR results are discrepant. Southern blot may also be considered if PCR detects only one allele, particularly with a rare repeat size, to determine whether the individual is truly homozygous or whether an HRE is present that failed to amplify.<sup>35</sup> Recently published testing guidelines for myotonic dystrophy, type 2, include performing Southern blot in all apparently homozygous cases.<sup>36</sup> Although up to 34% of individuals are expected to have homozygous *C9orf72* repeat sizes, rare homozygous repeats (3, 7, 11, and 12) are found in less than 1% (Matthew

Harms, MD, written communication, April 1, 2020); such cases could be targeted for additional testing. Southern blot and other methods capable of sizing the HRE remain important tools in the research setting and may be clinically necessary in the future if HRE size is clearly shown to affect disease expression.

### Genetic Counseling Should Be Provided to All Affected Persons

All persons with ALS or FTD should be provided genetic counseling, irrespective of whether they have a positive family history of ALS or FTD or are seeking genetic testing. A discussion of ALS and/or FTD genetics should introduce genetic heterogeneity, dominant transmission, disease expression, and penetrance, leading to the offer of *C9orf72* HRE testing for persons with European geoancestry.

### Provide Genetic Risk Assessment Informed by Family History

The family history is a fundamental aspect of genetic risk assessment and genetic counseling for persons with ALS or FTD. Clinicians should document a 3-generation pedigree, at minimum, that ascertains ALS, FTD, other dementias, parkinsonism, ataxia, psychiatric disorders, and suicide.<sup>33</sup> The pedigree should be reviewed for evidence of dominant transmission. However, many circumstances may obscure a clear pattern of dominant transmission in families with the *C9orf72* HRE,<sup>37</sup> and data from ALS clinic cohorts suggest that only about half of those who carry the HRE have a family history of ALS.<sup>38,39</sup> Family history information may be used to provide HRE risk assessment for affected persons who are considering HRE testing. See table 2 for HRE incidence estimates by diagnosis and family history.

### Empower Affected Persons to Make an Informed Decision About HRE Testing

Pretest counseling should prepare individuals for the possible impact of testing on themselves and their family. Cognitively impaired persons should be assisted by a legal guardian or health care proxy throughout the counseling and testing process. All affected persons and their families should be informed that testing for the most common genetic cause of ALS (or FTD) is available and that this is a personal/family choice. The availability of clinical trials should be discussed. The clinical heterogeneity and incomplete penetrance of the HRE should be emphasized. Patients and families should be informed of the limitations of HRE testing, including that (1)

**Table 3** *C9orf72* HRE Post-test Counseling Considerations for Persons With ALS, ALS-FTD, and FTD

Positive HRE result	Negative HRE result	Intermediate HRE result
Discuss range of symptoms (ALS, FTD, and psychiatric disease)	Discuss that a negative result does not exclude a genetic component in disease	Discuss that significance of intermediate repeats is unknown but may be incidental
Review clinical trials and other research opportunities	If family history of ALS or FTD, offer multigene panel	If family history of ALS or FTD, offer multigene panel
Discuss risks for specific family members, including children	If symptom onset <50 y, offer multigene panel	If symptom onset <50 y, offer multigene panel
Review option of presymptomatic testing for adult relatives	If no family history of ALS or history of dementia, recurrence risk to relatives is low	If no family history of ALS or history of dementia, recurrence risk to relatives is likely low
Provide test report and brief summary letter	Unaffected relatives not eligible for testing	Unaffected relatives not eligible for testing

Abbreviations: ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia; HRE = hexanucleotide repeat expansion.

a negative result does not exclude a genetic basis or contribution to the proband's condition, (2) rarely, an intermediate HRE of uncertain significance may be found, or the laboratory test may not be able to provide a result, and (3) positive results do not allow prediction of disease course.<sup>14,37</sup> Post-test counseling points for patients with positive, negative, and intermediate HRE test outcomes are outlined in table 3.

### Prepare Unaffected Family Members Who Seek Presymptomatic Testing

Presymptomatic testing for the *C9orf72* HRE may be offered to adult relatives of persons with a documented, pathogenic HRE. This clinical service requires extensive genetic counseling and is best provided by a certified genetic counselor and/or at a tertiary ALS or FTD clinic. Individuals seeking presymptomatic testing should be assessed for psychosocial readiness to receive the news of their genetic status and motivations for seeking testing explored. Pretest counseling should review risks and legal protections pertaining to genetic discrimination. Most importantly, the limitations of testing must be emphasized. A positive result does not resolve uncertainty regarding disease expression, age at onset, or whether disease will actually occur. Most patients seek testing to determine whether they will develop ALS or FTD, but we currently cannot predict whether a healthy HRE carrier will develop ALS, FTD, both, or neither. Although some studies have suggested that penetrance approaches 90%–100% by age 80, other evidence suggests a far lower penetrance.<sup>9,29,32</sup> This uncertainty has affected clinical practice, and family members undergoing presymptomatic testing at different centers have reported being told widely different disease risks. Providing specific risk figures conveys a degree of certainty that does not exist for the individual patient at this time and is not recommended. Many HRE carriers will die from other causes; thus, stating penetrance figures based on a theoretical 80- or 90-year lifespan may be misleading. Until penetrance is better understood, at-risk persons should be told that testing can determine whether they inherited their family's predisposition to ALS and/or FTD, and the magnitude of that risk is not precisely known

but increases with age. HRE carriers should also know that they have a 50% chance to pass on the HRE to each child whether or not they themselves develop disease.

## Goals for Future Research

### Develop Evidence-based Guidelines for ALS and FTD Genetic Testing and Counseling

There is currently no consistent approach to the offer of testing for the typical ALS or FTD patient, who has no family history of the disease. Many patients who desire testing and counseling are not offered these services.<sup>18</sup> A recent survey of ALS clinicians revealed that 74% would be more likely to offer ALS genetic testing if testing guidelines were published.<sup>17</sup> Genetic testing guidelines have been published for other neurodegenerative diseases such as Huntington and Alzheimer disease<sup>40,41</sup> and successfully incorporated into patient care. Consistent genetic testing practices would also support the identification of appropriate patients for gene-targeted trials and therapies.

Although further study is needed regarding the minimum HRE size necessary to cause disease, commercial laboratories are in urgent need of guidance to ensure consistent interpretations of HRE sizes. Currently, intermediate or smaller expansions could be interpreted differently at different laboratory tests, potentially leading to discrepant and/or inaccurate results for patients or family members undergoing diagnostic or presymptomatic testing.<sup>23,24</sup> Laboratories, clinicians, and patients could benefit from guidelines establishing consistent HRE cutoffs, which will likely require updating as new information becomes available. Given that some affected HRE carriers have been found to carry pathogenic variants in other genes, it is unclear whether additional genetic should be offered after a patient tests positive for the HRE. Guidance is also needed to arm genetic counselors and other clinicians with a consistent message regarding penetrance of the *C9orf72* HRE. The development of evidence-based guidelines that encompass HRE test indication, methodology, interpretation, and genetic counseling would

**Table 4** Summary of Practice Recommendations and Goals for Research

Practice recommendations
All persons with ALS or FTD of European geoancestry should be offered <i>C9orf72</i> HRE testing
Amplicon length analysis with bidirectional RP-PCR is currently the best approach for clinical testing for the HRE
Genetic counseling should be provided to all persons with ALS or FTD, irrespective of family history
Goals for future research
Develop consensus guidelines for genetic testing and counseling for the <i>C9orf72</i> HRE
Prioritize <i>C9orf72</i> as a target for clinical trials
Engage diverse patients in <i>C9orf72</i> research

Abbreviations: ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia; HRE = hexanucleotide repeat expansion.

support clinicians and laboratories in providing consistent and equitable testing and care.

### Prioritize *C9orf72* as a Target for Clinical Trials

Recent data from clinic-based cohorts has shown that the relative contribution of the *C9orf72* HRE, as compared to other ALS genes, is even greater than initial estimates suggested. Among more than 500 ALS patients tested via the ALS Genetic Access program of the Northeast ALS Consortium, the HRE accounted for 75% of all pathogenic or likely pathogenic variants identified in the 6 genes tested (unpublished data). Similarly, the HRE comprised 79% of pathogenic or likely pathogenic variants detected in a Midwestern clinic cohort; testing included comprehensive multigene panel testing for familial or early onset cases. The incidence of pathogenic or likely pathogenic variants in *SOD1* and in genes other than *C9orf72* in clinic-based ALS cases in the United States may be lower than that reported in research cohorts.<sup>39</sup> Accordingly, research and industry should prioritize the *C9orf72* HRE as a target for therapy. Carriers of the HRE are present in every ALS and FTD clinic, and with consistent testing practices, they will be increasingly identified. They represent a rich opportunity to study the natural history of the condition, identify early biomarkers of disease, and ultimately, develop gene-targeted therapies and neuroprotective interventions. With coordinated effort from the scientific community, the next generation of HRE carriers may stand to benefit.

### Engage Diverse Patients in Research

Further study is needed to better understand the incidence of the HRE in diverse populations. Our current understanding of the familial and genetic basis of ALS and FTD is based on the study of White individuals, and data thus derived (such as published empiric recurrence risks) may not be applicable to other populations.<sup>37</sup> Although the HRE has

been identified in persons with ALS in Europe, North and South America, and East and South Asia,<sup>9</sup> incidence has not been extensively studied in many populations. Data on the genetic profile of sporadic and familial ALS and FTD in persons of diverse geoancestry are critical to determine the need for population-specific testing approaches. It is currently unclear, for example, whether the universal offer of HRE testing is warranted in affected persons of non-European descent. Likewise, for familial ALS or FTD cases of non-European descent, it is uncertain whether the first step of testing should be multigene panel testing or HRE testing. The success of ALS and FTD research hinges on successfully recruiting and retaining patients of diverse backgrounds. Table 4 summarizes practice recommendations and goals for future research.

## Conclusion

The discovery of the *C9orf72* HRE marked the finish line in the long search for the underlying cause of chromosome 9-linked FTD and ALS. The work of applying the many clinical implications of this discovery then began, and much progress has been made in the 10 years since. Commercial testing for the HRE is now widely available, and many clinicians are offering testing to persons with familial ALS. Going forward, several important steps will continue to advance patient care, research, and therapy. This includes the development of consensus guidelines for the genetic testing and counseling of persons with ALS and FTD, including the offer of HRE testing to all affected persons of European geoancestry, recommendations for consistent repeat size cutoffs and interpretation, and guidance in providing counseling regarding penetrance and other issues. Given that the HRE accounts for a significant majority of pathogenic variants identified in clinical testing in the North America and Europe, *C9orf72* should be prioritized as a target for gene-specific therapies. Finally, researchers should recruit and engage affected persons of diverse backgrounds to understand the genetic profile of ALS and FTD in all populations. Achieving these goals represents the next milestone in the work of understanding and treating the *C9orf72* HRE.

### Author Contribution

J. Roggenbuck: Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data.

### Acknowledgment

The author thanks Dr. Stephen Kolb for helpful comments on the manuscript, Courtney Fleming for assistance with the figure, and Leah Vicini for assistance with the supplementary tables.

### Study Funding

No targeted funding reported.

## Disclosure

J. Roggenbuck received support from the OSUWMC Neurological Research Institute and the Julie Bonasera Fund for ALS and Neuromuscular Diseases. Go to [Neurology.org/NG](http://Neurology.org/NG) for full disclosures.

## Publication History

Received by *Neurology: Genetics* July 25, 2020. Accepted in final form October 19, 2020.

## References

- Vance C, Al-Chalabi A, Ruddy D, et al. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2–21.3. *Brain* 2006;129:868–876. doi: 10.1093/brain/awl030.
- DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* 2011;72:245–256. doi: 10.1016/j.neuron.2011.09.011.
- Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 2011;72:257–268. doi: 10.1016/j.neuron.2011.09.010.
- Balendra R, Isaacs AM. C9orf72-mediated ALS and FTD: multiple pathways to disease. *Nat Rev Neurol* 2018;14:544–558. doi: 10.1038/s41582-018-0047-2.
- Beck J, Poulter M, Hensman D, et al. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. *Am J Hum Genet* 2013;92:345–353. doi: 10.1016/j.ajhg.2013.01.011.
- Rohrer JD, Isaacs AM, Mizielinska S, et al. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. *Lancet Neurol* 2015;14:291–301. doi: 10.1016/S1474-4422(14)70233-9.
- Boeve BF, Boylan KB, Graff-Radford NR, et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. *Brain* 2012;135:765–783. doi: 10.1093/brain/aws004.
- Langenhove TV, van der Zee J, Gijssels I, et al. Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLD cohort. *JAMA Neurol* 2013;70:365–373. doi: 10.1001/2013.jamaneurol.181.
- Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. *Lancet Neurol* 2012;11:323–330. doi: 10.1016/S1474-4422(12)70043-1.
- Tsai CP, Soong BW, Tu P-H, et al. A hexanucleotide repeat expansion in C9ORF72 causes familial and sporadic ALS in Taiwan. *Neurobiol Aging* 2012;33:2232.e11–2232.e18. doi: 10.1016/j.neurobiolaging.2012.05.002.
- Jang JH, Kwon MJ, Choi WJ, et al. Analysis of the C9orf72 hexanucleotide repeat expansion in Korean patients with familial and sporadic amyotrophic lateral sclerosis. *Neurobiol Aging* 2013;34:1311.e7–1311.e9. doi: 10.1016/j.neurobiolaging.2012.09.004.
- Konno T, Shiga A, Tsujino A, et al. Japanese amyotrophic lateral sclerosis patients with GGGGCC hexanucleotide repeat expansion in C9ORF72. *J Neurol Neurosurg Psychiatry* 2013;84:398–401. doi: 10.1136/jnnp-2012-302272.
- Zou ZY, Li XG, Liu MS, Cui LY. Screening for C9orf72 repeat expansions in Chinese amyotrophic lateral sclerosis patients. *Neurobiol Aging* 2013;34:1710.e5–1710.e6. doi: 10.1016/j.neurobiolaging.2012.11.018.
- Fong JC, Karydas AM, Goldman JS. Genetic counseling for FTD/ALS caused by the C9ORF72 hexanucleotide expansion. *Alzheimers Res Ther* 2012;4:27. doi: 10.1186/alzrt130.
- Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2009;73:1227–1233. doi: 10.1212/WNL.0b013e3181bc01a4.
- Andersen PM, Borasio GD, Dengler R, et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. *Eur J Neurol* 2005;12:921–938. doi: 10.1111/j.1468-1331.2005.01351.x.
- Klepek H, Nagaraja H, Goutman SA, Quick A, Kolb SJ, Roggenbuck J. Lack of consensus in ALS genetic testing practices and divergent views between ALS clinicians and patients. *Amyotroph Lateral Scler Frontotemporal Degener* 2019;20:216–221. doi: 10.1080/21678421.2019.1582670.
- Wagner KN, Nagaraja H, Allain DC, Quick A, Kolb S, Roggenbuck J. Patients with amyotrophic lateral sclerosis have high interest in and limited access to genetic testing. *J Genet Couns* 2017;26:604–611. doi: 10.1007/s10897-016-0034-y.
- Wagner KN, Nagaraja HN, Allain DC, Quick A, Kolb SJ, Roggenbuck J. Patients with sporadic and familial amyotrophic lateral sclerosis found value in genetic testing. *Mol Genet Genomic Med* 2018;6:224–229. doi: 10.1002/mgg3.360.
- Fanos JH, Gelinus DF, Miller RG. “You have shown me my end”: attitudes toward presymptomatic testing for familial amyotrophic lateral sclerosis. *Am J Med Genet A* 2004;129A:248–253. doi: 10.1002/ajmg.a.30178.
- Akimoto C, Volk AE, van Blitterswijk M, et al. A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. *J Med Genet* 2014;51:419–424. doi: 10.1136/jmedgenet-2014-102360.
- Nordin A, Akimoto C, Wuolikainen A, et al. Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. *Amyotroph Lateral Scler Frontotemporal Degener* 2017;18:256–264. doi: 10.1080/21678421.2016.1262423.
- Crook A, McEwen A, Fifita JA, et al. The C9orf72 hexanucleotide repeat expansion presents a challenge for testing laboratories and genetic counseling. *Amyotroph Lateral Scler Frontotemporal Degener* 2019;20:310–316. doi: 10.1080/21678421.2019.1588904.
- Klepek H, Goutman SA, Quick A, Kolb SJ, Roggenbuck J. Variable reporting of C9orf72 and a high rate of uncertain results in ALS genetic testing. *Neurol Genet* 2019;5:e301. doi: 10.1212/NXG.0000000000000301.
- van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. *Lancet Neurol* 2013;12:978–988. doi: 10.1016/S1474-4422(13)70210-2.
- Fournier C, Barbier M, Camuzat A, et al. Relations between C9orf72 expansion size in blood, age at onset, age at collection and transmission across generations in patients and presymptomatic carriers. *Neurobiol Aging* 2019;74:234.e1–234.e8. doi: 10.1016/j.neurobiolaging.2018.09.010.
- Jackson JL, Finch NA, Baker MC, et al. Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers. *Mol Neurodegener* 2020;15:7. doi: 10.1186/s13024-020-0359-8.
- Gendron TF, Belzil VV, Zhang YJ, Petrucelli L. Mechanisms of toxicity in C9FTLD/ALS. *Acta Neuropathol* 2014;127:359–376. doi: 10.1007/s00401-013-1237-z.
- Murphy NA, Arthur KC, Tienari PJ, Houlden H, Chiò A, Traynor BJ. Age-related penetrance of the C9orf72 repeat expansion. *Sci Rep* 2017;7:2116. doi: 10.1038/s41598-017-02364-1.
- Ross JP, Leblond CS, Laurent SB, et al. Oligogenicity, C9orf72 expansion, and variant severity in ALS. *Neurogenetics* 2020;21:227–242. doi: 10.1007/s10048-020-00612-7.
- van der Zee J, Gijssels I, Dillen L, et al. A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. *Hum Mutat* 2013;34:363–373. doi: 10.1002/humu.22244.
- Turner MR, Al-Chalabi A, Chio A, et al. Genetic screening in sporadic ALS and FTD. *J Neurol Neurosurg Psychiatry* 2017;88:1042–1044. doi: 10.1136/jnnp-2017-315995.
- Roggenbuck J, Fong JC. Genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia. *Clin Lab Med* 2020;40:271–287. [ClinicalKey. Available at: <https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S0272721220300342?returnurl=null&referrer=null>. Accessed July 20, 2020.](https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S0272721220300342?returnurl=null&referrer=null)
- Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. *Nat Rev Neurol* 2017;13:96–104. doi: 10.1038/nrneurol.2016.182.
- Cleary EM, Pal S, Azam T, et al. Improved PCR based methods for detecting C9orf72 hexanucleotide repeat expansions. *Mol Cell Probes* 2016;30:218–224. doi: 10.1016/j.mcp.2016.06.001.
- Schoser B, Montagnese F, Basse G, et al. Consensus-based care recommendations for adults with myotonic dystrophy type 2. *Neurol Clin Pract* 2019;9:343–353. doi: 10.1212/CPJ.0000000000000645.
- Roggenbuck J, Quick A, Kolb SJ. Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians. *Genet Med* 2017;19:267–274. doi: 10.1038/gim.2016.107.
- Umoh ME, Fournier C, Li Y, et al. Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. *Neurology* 2016;87:1024–1030. doi: 10.1212/WNL.0000000000003067.
- Roggenbuck J, Palettas M, Vicini L, Patel R, Quick A, Kolb SJ. Incidence of pathogenic, likely pathogenic, and uncertain ALS variants in a clinic cohort. *Neurol Genet* 2020;6:e390. doi: 10.1212/NXG.0000000000000390.
- Nance MA. Genetic testing of children at risk for Huntington’s disease. *US Huntington Disease Genetic Testing Group. Neurology* 1997;49:1048–1053. doi: 10.1212/wnl.49.4.1048.
- Goldman J, Farmer J, Deerlin VV, Wilhelmsen K, Miller B, Grossman M. Frontotemporal dementia: genetics and genetic counseling dilemmas. *Neurologist* 2004;10:227–234. doi: 10.1097/01.nrl.0000138735.48533.26.

# Neurology<sup>®</sup> Genetics

## ***C9orf72* and the Care of the Patient With ALS or FTD: Progress and Recommendations After 10 Years**

Jennifer Roggenbuck

*Neurol Genet* 2021;7;

DOI 10.1212/NXG.0000000000000542

**This information is current as of December 21, 2020**

*Neurol Genet* is an official journal of the American Academy of Neurology. Published since April 2015, it is an open-access, online-only, continuous publication journal. Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2376-7839.





<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://ng.neurology.org/content/7/1/e542.full.html">http://ng.neurology.org/content/7/1/e542.full.html</a>
<b>References</b>	This article cites 41 articles, 6 of which you can access for free at: <a href="http://ng.neurology.org/content/7/1/e542.full.html##ref-list-1">http://ng.neurology.org/content/7/1/e542.full.html##ref-list-1</a>
<b>Citations</b>	This article has been cited by 2 HighWire-hosted articles: <a href="http://ng.neurology.org/content/7/1/e542.full.html##otherarticles">http://ng.neurology.org/content/7/1/e542.full.html##otherarticles</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>All Genetics</b> <a href="http://ng.neurology.org/cgi/collection/all_genetics">http://ng.neurology.org/cgi/collection/all_genetics</a> <b>Amyotrophic lateral sclerosis</b> <a href="http://ng.neurology.org/cgi/collection/amyotrophic_lateral_sclerosis">http://ng.neurology.org/cgi/collection/amyotrophic_lateral_sclerosis</a> <b>Frontotemporal dementia</b> <a href="http://ng.neurology.org/cgi/collection/frontotemporal_dementia">http://ng.neurology.org/cgi/collection/frontotemporal_dementia</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: <a href="http://ng.neurology.org/misc/about.xhtml#permissions">http://ng.neurology.org/misc/about.xhtml#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://ng.neurology.org/misc/addir.xhtml#reprintsus">http://ng.neurology.org/misc/addir.xhtml#reprintsus</a>

*Neurol Genet* is an official journal of the American Academy of Neurology. Published since April 2015, it is an open-access, online-only, continuous publication journal. Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Online ISSN: 2376-7839.

